Scope, claims, and US patent landscape for “US Drug Patent 11,357,738” (composition of CF3(CF2)5(CH2)7CH3 with ≤10 wt% CF3-(CF2)5-CH(CH3)-(CH2)5-CH3)
US Patent 11,357,738 is claim-focused on a narrowly defined perfluorinated hydrocarbon-like composition dominated by CF3(CF2)5(CH2)7CH3 (≥90 wt%) with controlled impurity/alternate isomer content of CF3-(CF2)5-CH(CH3)-(CH2)5-CH3 (≤10 wt%), with additional dependent limitations directed to composition purity, clear-liquid formulation, substantially polymer-free / perfluorinated-free / no dissolved API, low dynamic viscosity (≤10 mPa·s), optical property window (refractive index 1.30–1.35 at 20°C), and a kit/container with ophthalmic drop dispensing (8–15 µL).
Actionable bottom line: the enforceable scope is strongest where a product is (i) an ophthalmic-use liquid or clear solution, (ii) contains the specified perfluoroalkane blend with the dominant-isomer ratio, and (iii) matches the viscosity and optionally refractive index windows, plus the dropper-based kit configuration. Products deviating on composition ratio, physical parameters, or delivery format are the primary design-arounds.
What is US Patent 11,357,738 claiming and how narrow is the composition?
Featured snippet answer: The patent claims a “composition consisting essentially of” two specific fluorinated molecules, with CF3(CF2)5(CH2)7CH3 ≥90 wt% and CF3-(CF2)5-CH(CH3)-(CH2)5-CH3 ≤10 wt%, optionally with tighter ranges to ≤5 wt% and ≤3 wt%, plus dependent limits on being a clear liquid solution, low viscosity, refractive index, and an ophthalmic dispensing kit.
Independent claim 1: core scope (dominant component + isomer control)
Claim 1 covers a composition:
- “consisting essentially of” two named components:
- CF3(CF2)5(CH2)7CH3
- CF3-(CF2)5-CH(CH3)-(CH2)5-CH3
- With a composition ratio:
- CF3(CF2)5(CH2)7CH3 ≥90 wt%
- CF3-(CF2)5-CH(CH3)-(CH2)5-CH3 ≤10 wt%
Key legal/technical read-through (claim construction implications):
- “Consisting essentially of” is a middle ground between open and closed language. It permits other components only if they do not materially affect the claimed properties/novelty. In practice, the dependent claims further constrain what else is tolerated (claim 6: substantially free of polymer/perfluorinated compound/dissolved API).
- Because the ratio is the gate, analytical characterization (GC/MS, NMR, or equivalent) becomes central in infringement and validity fights.
Dependent claims 2–4: tightening purity to lock in the blend
These add progressively tighter limits:
- Claim 2: ≥95 wt% dominant; ≤5 wt% minor
- Claim 3: ≥97 wt% dominant; ≤3 wt% minor
- Claim 4: “consists of” the two components with up to 3 wt% of the minor component (i.e., no other “consisting essentially of” latitude)
Enforcement impact: any product that can be shown to contain the required two-component blend but with other constituents may still be pulled into claim 1 if those constituents are argued not to materially affect the blend’s defining characteristics. Claim 4 is harder to avoid because it is closer to a true “consists of” closure (limited to the two components within the specified ratio).
What formulation and physical-property limitations control infringement?
Is it required to be a clear liquid solution?
- Claim 5: composition of claim 1 formulated as a clear liquid solution.
If a product is a suspension, emulsion, or otherwise not a clear solution, it is positioned to avoid claim 5 even if it contains the same ratio of the two components.
What impurity/exclusion language matters?
- Claim 6: composition of claim 1 is substantially free of:
- (a) a polymer
- (b) a perfluorinated compound, and/or
- (c) a dissolved pharmacologically active ingredient
Important nuance: the claim uses disjunctive wording “and/or,” so the “substantially free” restriction is broad. If the product contains additional perfluorinated species beyond the two named components, that can be used to argue non-infringement of claim 6 even if claim 1 might still be argued under “consisting essentially of.”
Does viscosity limit the claimed product?
- Claim 7: dynamic viscosity ≤10 mPa·s.
This is a clean technical design-around lever. Many formulation changes (temperature, viscosity modifiers, stabilizers) affect mPa·s-level behavior. Even if the blend ratios match, failing the viscosity ceiling can remove coverage at least for claims that depend on claim 7.
Is a refractive index window claimed?
- Claim 14: (from claim 5) refractive index 1.30 to 1.35 at 20°C.
This adds an objective optical gate. If a product’s measured refractive index falls outside the band (depending on temperature control and measurement method), infringement for claim 14 becomes more contestable.
What does the kit/ophthalmic delivery claims add to the patent scope?
Claim 15: kit defined by dispensing means for lacrimal sac/lower eyelid/eye surface/ophthalmic tissue
- Claim 15: a kit comprising the composition and a container with dispensing means adapted for topical administration to ophthalmic tissues including:
- lacrimal sac
- lower eyelid
- eye surface
- ophthalmic tissue
This claim shifts enforcement from chemical composition alone to a product-and-device bundle: a liquid-filled ophthalmic container designed to apply drops to the eye.
Claims 16–18: droplet volume range tied to dropper dimensions
- Claim 16: dropper adapted to dispense droplets 8 to 15 µL
- Claim 17: 8 to 12 µL
- Claim 18: about 10 µL
Enforcement implication: even with a composition that matches claim 1, a supplier using a different dropper system with materially different droplet volume may avoid the dependent kit claims. This makes the device design and measured droplet calibration a second infringement battleground.
How does “consisting essentially of” vs “consists of” affect design-around strategy?
Within this family of claims:
- Claim 1 and claim 2/3/5/6/7/14/15 use “consisting essentially of” (or incorporate claim 1), which is more flexible for other trace constituents, so long as they do not materially affect the composition’s properties.
- Claim 4 is closer to “consists of” (within the two-component frame) and is harder to evade if other components are present above trace levels or if the minor component is above the stated threshold.
Practical risk posture:
- A generic/competitor attempting to copy the blend ratio can face claim 4 exposure if they also have the “up to 3 wt%” minor component but cannot purge other components.
- A competitor changing the product so it includes other perfluorinated additives can reduce claim 6 risk, but it can still be argued to remain within “consisting essentially of” for claim 1 if those additives do not “materially affect” the composition’s defining properties.
What is the competitive patent landscape likely to look like around this composition?
No additional patent numbers, assignees, prosecution history, or related family members were provided with the prompt. Under the strict constraint that a complete and accurate landscape cannot be produced without those bibliographic/legal details, the analysis below focuses on where the claims place competitors and how other IP typically clusters for composition-of-matter plus ophthalmic kits.
Likely adjacency clusters to search around US 11,357,738
-
Same-molecule composition variants
- different wt% ranges
- “consisting essentially of” vs “consists of”
- alternative impurity/isomer definitions
-
Physical property formulations
- viscosity ranges
- refractive index windows
- “clear solution” constraints
-
Ophthalmic methods and kits
- drop size, delivery time, container format
- lacrimal sac targeting language
- sterility/packaging constraints (not stated in provided claims but commonly attached to ophthalmic compositions)
-
Uses and method-of-treatment
- the provided claims are composition/kit oriented, but portfolios in this space often overlap with method-of-use patents once the composition is paired with a therapeutic effect
Where infringement risk concentrates for products in this area
- If the product is marketed as an ophthalmic drop and uses a dropper volume calibrated to 8–15 µL (or 10 µL), kit claims 15–18 become more directly relevant.
- If the product uses the claimed blend as a primary formulation excipient/active-like component (even if not “pharmacologically active”), claim 6’s “dissolved pharmacologically active ingredient” language can be litigated based on whether any API is dissolved in the liquid.
What Orange Book status, Paragraph IV, and FDA exclusivity apply?
No drug name, reference product, application number, FDA submission details, or Orange Book listing were provided. The prompt only references the US patent number. Without the FDA listing data, exclusivity triggers, and challenge status, a complete and accurate exclusivity/timeline and Paragraph IV analysis cannot be produced.
Key Takeaways
- US 11,357,738 is centered on a two-component perfluorinated blend: CF3(CF2)5(CH2)7CH3 as the dominant species (≥90 wt%) with CF3-(CF2)5-CH(CH3)-(CH2)5-CH3 as a controlled minor species (≤10 wt%), with tighter lock-ins in dependent claims.
- The enforceable perimeter expands with formulation and measured properties: clear liquid solution, dynamic viscosity ≤10 mPa·s, and refractive index 1.30–1.35 at 20°C.
- A second enforcement lever is ophthalmic kit architecture: container + dispensing means configured for lacrimal/eyelid/eye-surface delivery, with dropper droplet volumes of 8–15 µL, 8–12 µL, or ~10 µL depending on the dependent claim.
- Design-around most directly targets: the wt% ratio, avoidance of the ≤10 mPa·s viscosity ceiling, measured refractive index outside the band, addition of components that break “substantially free” limitations in claim 6, and device changes that yield droplet volumes outside the claimed ranges.
FAQs
-
If a product matches the wt% ratio but uses a non-clear formulation (emulsion), does it infringe claim 5?
Claim 5 depends on claim 1 and requires the composition is formulated as a “clear liquid solution,” so non-clear formulations target claim 5 and downstream dependent refractive index language.
-
How do the wt% thresholds change infringement exposure across claims 1–4?
Claims 1 covers ≥90/≤10; claim 2 covers ≥95/≤5; claim 3 covers ≥97/≤3; claim 4 tightens closure to essentially only those two components with up to 3 wt% of the minor component.
-
What measured-property tests matter most for litigation of claim 7 and claim 14?
Dynamic viscosity at relevant conditions for claim 7 (≤10 mPa·s) and refractive index measurement at 20°C for claim 14 (1.30–1.35) are decisive technical evidence points.
-
Can a competitor avoid the kit claims by changing dropper droplet volume?
Claims 16–18 are keyed to droplet volume ranges (8–15 µL, 8–12 µL, ~10 µL). Using a different dispensing system that yields materially different droplet volumes is the direct avoidance lever for those dependent kit claims.
-
How does claim 6’s “substantially free” language affect formulation design?
Claim 6 restricts the presence of polymer, additional perfluorinated compounds, and dissolved pharmacologically active ingredients. Formulators can target those categories to weaken dependent-claim coverage.
